Search results
Sandoz is a global leader in generic pharmaceuticals and biosimilars and a division of the Novartis Group. On this website, you can find the latest financial results, analyst presentations, listing prospectus and other investor-related information. Learn how Sandoz pioneers access for patients and creates value for shareholders.
Sandoz Norge er en ledende leverandør av generiske og biotilsvarende legemidler i Norge. Besøk vår nettside for å lære mer om våre produkter, vårt arbeid og vår visjon.
Sandoz Slovakia is a global leader in generic and biosimilar medicines, aiming to improve and extend human life. Learn more about our work and vision.
Sep 25, 2023 · Basel, September 25, 2023 — Novartis today confirmed plans for the 100% Spin-off of the Sandoz business, with trading of new Sandoz Group AG shares and ADRs (American Depositary Receipts) to commence on October 4, 2023. This follows the previously announced Novartis shareholder approval for the Spin-off of Sandoz, at the EGM on September 15 2023.
Aug 25, 2022 · Sandoz generated USD 9.6bn sales in 2021 sales and served 100+ markets globally with a strong presence in Europe as well as in the United States and Rest of World. Sandoz would leverage its strong brand and sustain its leading global position by continuing to invest in the key strategic areas of Biosimilars, Antibiotics and Generic Medicines.
www.sandoz.com is the official website of Sandoz, a global leader in generic and biosimilar medicines, and a division of Novartis. Find out more about the company's history, vision, and products.
Learn how to get in touch with Sandoz US, a leader in generic and biosimilar medicines, with offices across the country and a patient assistance program.
